Edgar Filing: BIOGEN IDEC INC. - Form 4

Form 4										
June 01, 2007 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue							OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5			
See Instru 1(b).		30(h) of the In	vestment (Company	y Act	of 19	40			
(Print or Type R	esponses)									
SHARP PHILIP A Symbol			Name and Ticker or Trading N IDEC INC. [BIIB]				5. Relationship of Reporting Person(s) to Issuer			
(Last)(First)(Middle)3. Date of (Month/Da14 CAMBRIDGE CENTER05/31/20			•			(Check all applicable) X_ Director 10% Owner Officer (give title below) Other (specify below)				
			ndment, Date Original hth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	GE, MA 02142						Person	More than One Ro	eporting	
(City)	(State) (2	Zip) Table	e I - Non-Do	erivative S	ecuri	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) o of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/31/2007		А	2,300	А	<u>(1)</u>	465,983	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOGEN IDEC INC. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	e Expiration D (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Am Underlying Sec (Instr. 3 and 4)		Securities	8. H Dei Sec (In:
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options (right to buy)	\$ 52.22	05/31/2007		А	5,950	(2)	05/30/2017	Common Stock	5,950	

Reporting Owners

Reporting Owner Name / Address	Relationships						
I O	Director	10% Owner	Officer	Other			
SHARP PHILIP A 14 CAMBRIDGE CENTER CAMBRIDGE, MA 02142	Х						
Signatures							
Robert A. Licht, Attorney in fa Sharp	0	6/01/2007	,				
**Signature of Reporting I		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted Stock Units were granted as an award for no consideration. Each Restricted Stock Unit represents the right to receive one share of BIIB common stock.
- (2) Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.
- (3) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.